JP2006518743A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006518743A5 JP2006518743A5 JP2006503721A JP2006503721A JP2006518743A5 JP 2006518743 A5 JP2006518743 A5 JP 2006518743A5 JP 2006503721 A JP2006503721 A JP 2006503721A JP 2006503721 A JP2006503721 A JP 2006503721A JP 2006518743 A5 JP2006518743 A5 JP 2006518743A5
- Authority
- JP
- Japan
- Prior art keywords
- solution
- emulsion
- cancer
- dihydrosphingosine
- sphingolipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000243 solution Substances 0.000 claims 29
- 239000000839 emulsion Substances 0.000 claims 24
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 18
- 150000003408 sphingolipids Chemical class 0.000 claims 17
- OTKJDMGTUTTYMP-ROUUACIJSA-N Safingol ( L-threo-sphinganine) Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ROUUACIJSA-N 0.000 claims 12
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 claims 12
- 235000014655 lactic acid Nutrition 0.000 claims 9
- 239000004310 lactic acid Substances 0.000 claims 9
- OTKJDMGTUTTYMP-QZTJIDSGSA-N (2r,3r)-2-aminooctadecane-1,3-diol Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](N)CO OTKJDMGTUTTYMP-QZTJIDSGSA-N 0.000 claims 8
- 150000003904 phospholipids Chemical class 0.000 claims 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 5
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims 4
- 239000003381 stabilizer Substances 0.000 claims 4
- 239000007951 isotonicity adjuster Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 2
- 239000012736 aqueous medium Substances 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 239000008347 soybean phospholipid Substances 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229950008902 safingol Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44953603P | 2003-02-21 | 2003-02-21 | |
| US60/449,536 | 2003-02-21 | ||
| PCT/US2004/004960 WO2004075834A2 (en) | 2003-02-21 | 2004-02-19 | Stabilized pharmaceutical compositions of safingol and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010290577A Division JP2011126886A (ja) | 2003-02-21 | 2010-12-27 | サフィンゴールの医薬組成物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006518743A JP2006518743A (ja) | 2006-08-17 |
| JP2006518743A5 true JP2006518743A5 (enExample) | 2007-04-05 |
| JP4842800B2 JP4842800B2 (ja) | 2011-12-21 |
Family
ID=32927531
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503721A Expired - Fee Related JP4842800B2 (ja) | 2003-02-21 | 2004-02-19 | サフィンゴールの医薬組成物およびその使用方法 |
| JP2010290577A Withdrawn JP2011126886A (ja) | 2003-02-21 | 2010-12-27 | サフィンゴールの医薬組成物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010290577A Withdrawn JP2011126886A (ja) | 2003-02-21 | 2010-12-27 | サフィンゴールの医薬組成物およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7476692B2 (enExample) |
| EP (1) | EP1594488B1 (enExample) |
| JP (2) | JP4842800B2 (enExample) |
| AT (1) | ATE331507T1 (enExample) |
| CA (1) | CA2516399C (enExample) |
| DE (1) | DE602004001393T2 (enExample) |
| ES (1) | ES2270347T3 (enExample) |
| MX (1) | MXPA05008860A (enExample) |
| WO (1) | WO2004075834A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007233155B2 (en) | 2006-03-29 | 2012-04-26 | Scitech Development Llc | Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery |
| JP2013510878A (ja) * | 2009-11-12 | 2013-03-28 | テキサス テック ユニバーシティー | 高増殖性障害を処置する組成物および方法 |
| EP3024441A4 (en) * | 2013-07-25 | 2017-04-19 | Nemucore Medical Innovations, Inc. | Nanoemulsions of hydrophobic platinum derivative |
| IT201600105201A1 (it) * | 2016-10-19 | 2018-04-19 | Nutrilinea Srl | Uso della fosfatidilserina per la prevenzione e il trattamento dei disturbi della prostata e relative composizioni farmaceutiche e nutraceutiche |
| US10034895B2 (en) * | 2017-11-30 | 2018-07-31 | Joel Steven Goldberg | Local application of D-lactic acid dimer is selectively cytotoxic when applied to cancer cells |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0716589A4 (en) * | 1993-07-23 | 1997-06-11 | Morris Herstein | COSMETIC COMPOSITION STIMULATING THE RENEWAL OF THE SKIN WITH A PROLONGED IRRITATION ELIMINATION EFFECT |
| WO1997014412A1 (en) * | 1994-08-26 | 1997-04-24 | Mary Kay Inc. | Topically applied, structural cellulite treatments |
| US5635536A (en) * | 1994-12-07 | 1997-06-03 | Pharmacia & Upjohn Aktiebolag | Emulsion suitable for administering a sphingolipid |
| ATE409486T1 (de) * | 1998-06-29 | 2008-10-15 | Children S Hospital Los Angele | Behandlung hyperproliferativer erkrankungen |
| US6368831B1 (en) * | 1998-06-29 | 2002-04-09 | Childrens Hospital Los Angeles | Treatment of hyperproliferative disorders |
| JP3220434B2 (ja) * | 1998-12-28 | 2001-10-22 | 花王株式会社 | 化粧料 |
| KR100343885B1 (ko) * | 1999-07-20 | 2002-07-19 | 주식회사 두산 | 파이토스핑고신의 수용액의 제조 방법 |
| KR100371491B1 (ko) * | 1999-07-27 | 2003-02-07 | 주식회사 두산 | 피부 보호용 크림조성물 |
| US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| JP3896234B2 (ja) * | 1999-12-24 | 2007-03-22 | 花王株式会社 | 化粧料 |
| EP1287815A1 (en) * | 2001-08-31 | 2003-03-05 | Cosmoferm B.V. | Use of a sphingoid base for inhibiting ceramidase activity |
| CN100340227C (zh) * | 2001-12-10 | 2007-10-03 | 花王株式会社 | 神经酰胺类乳化物 |
| JP4220698B2 (ja) * | 2001-12-10 | 2009-02-04 | 花王株式会社 | 皮膚外用剤 |
| JP4119646B2 (ja) * | 2001-12-10 | 2008-07-16 | 花王株式会社 | セラミド類乳化物の製造法 |
| PL373235A1 (en) * | 2002-09-05 | 2005-08-22 | Galderma S.A. | Solution for ungual application |
-
2004
- 2004-02-19 EP EP04712898A patent/EP1594488B1/en not_active Expired - Lifetime
- 2004-02-19 ES ES04712898T patent/ES2270347T3/es not_active Expired - Lifetime
- 2004-02-19 JP JP2006503721A patent/JP4842800B2/ja not_active Expired - Fee Related
- 2004-02-19 CA CA2516399A patent/CA2516399C/en not_active Expired - Fee Related
- 2004-02-19 AT AT04712898T patent/ATE331507T1/de not_active IP Right Cessation
- 2004-02-19 US US10/782,459 patent/US7476692B2/en active Active
- 2004-02-19 WO PCT/US2004/004960 patent/WO2004075834A2/en not_active Ceased
- 2004-02-19 DE DE602004001393T patent/DE602004001393T2/de not_active Expired - Lifetime
- 2004-02-19 MX MXPA05008860A patent/MXPA05008860A/es active IP Right Grant
-
2010
- 2010-12-27 JP JP2010290577A patent/JP2011126886A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6392209B2 (ja) | 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア | |
| US20090047336A1 (en) | novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation | |
| JP2013500239A5 (enExample) | ||
| JP2006502233A (ja) | 白金凝集物およびその製造方法 | |
| JP2021152032A (ja) | トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療 | |
| CN1798544A (zh) | 喜树碱和氟嘧啶的组合物 | |
| TW201632176A (zh) | 治療癌症之奈米粒子及其用途 | |
| ES2770113T3 (es) | Análogos de la cisteamina resistentes a la ADO y sus usos | |
| BRPI0510778B1 (pt) | Composição farmacêutica, processo para preparação da :mesma, e, uso de uma composição | |
| JP2006518743A5 (enExample) | ||
| CN116688137B (zh) | 一种基于核壳结构的药物组合物及应用 | |
| AU2005284909B2 (en) | Delivering iron to an animal | |
| KR100313149B1 (ko) | 셀레질린을함유하는리포솜조성물 | |
| TWI492759B (zh) | 膽甾烷醇衍生物之併用用途 | |
| JP2009521400A (ja) | ヒアルロン酸リン脂質合成物を含む経口関節機能改善と保護剤 | |
| JP2011126886A (ja) | サフィンゴールの医薬組成物およびその使用方法 | |
| JP2024526791A (ja) | リポソーム製剤の調製方法 | |
| JP2008501782A5 (enExample) | ||
| US20230144385A1 (en) | Ethanolamine formulation for treating epithelial ovarian carcinoma | |
| JP2000302685A (ja) | 抗腫瘍薬含有リポソーム製剤 | |
| WO2025012723A1 (en) | Liposome encapsulated apomorphine | |
| JP2015209417A (ja) | 経口疾患治療薬 | |
| Musheer et al. | Formulation, Development and Characterization of Effective Niosomal Drug Delivery System for the Treatment of Diabetes Mellitus | |
| WO2023190709A1 (ja) | リポソーム組成物およびリポソームを含む医薬組成物 | |
| WO2007006232A1 (fr) | Complexe de phospholipide et d’acide hyaluronique et procédé de préparation |